scholarly journals Long-term progression-free survival of apatinib monotherapy for relapsed ovarian cancer: a case report and literature review

2019 ◽  
Vol Volume 12 ◽  
pp. 3635-3644 ◽  
Author(s):  
Di Zhang ◽  
Jiaqi Huang ◽  
Yulan Sun ◽  
Qisen Guo
Keyword(s):  
Ovarian Cancer ◽  
Case Report ◽  
Literature Review ◽  
Progression Free Survival ◽  
Free Survival

scholarly journals Endostar Plus Apatinib Successfully Achieved Long Term Progression-Free Survival in Refractory Ovarian Cancer: A Case Report and Literature Review

2021 ◽  
Vol Volume 14 ◽  
pp. 5363-5372
Author(s):  
Chunmei Xiao ◽  
Fangye Xu ◽  
Rong Wang ◽  
Qi Liang ◽  
Kai Shen ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Case Report ◽  
Literature Review ◽  
Progression Free Survival ◽  
Free Survival

Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer

2003 ◽  
Vol 13 (Suppl 2) ◽  
pp. 144-148 ◽  
Author(s):  
M. J. Piccart ◽  
K. Bertelsen ◽  
G. Stuart ◽  
J. Cassidy ◽  
C. Mangioni ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Randomized Clinical Trials ◽  
Advanced Ovarian Cancer ◽  
Progression Free Survival ◽  
Clinical Response Rate ◽  
Free Survival ◽  
Long Term Follow Up ◽  
Clinically Significant

Two independent and consecutive randomized clinical trials, conducted by the American Gynecological Oncology Group and by an European–Canadian Intergroup, have shown superiority, in clinical response rate, progression-free survival, and overall survival, of a cisplatin–paclitaxel regimen over cisplatin–cyclophosphamide given as first-line chemotherapy for women with advanced epithelial ovarian cancer. The results of these studies, published with a median follow-up of about 3 years, have been updated with a 6.5-year follow-up: In each case, an 11% absolute gain in survival favoring the paclitaxel arm is shown; this advantage remains both statistically and clinically significant and supports a role for paclitaxel in frontline chemotherapy for advanced ovarian cancer.

scholarly journals Long-term Recurrence-free Survival in a Patient with Primary Hepatic Carcinosarcoma: Case Report with a Literature Review

2009 ◽  
Vol 40 (2) ◽  
pp. 166-173 ◽  
Author(s):  
Y. Yamamoto ◽  
H. Ojima ◽  
K. Shimada ◽  
H. Onaya ◽  
N. Hiraoka ◽  
...  
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
Hepatic Carcinosarcoma
Sign in / Sign up

Export Citation Format

Share Document